Lavior Pharma Inc., an International advanced diabetic wound and skincare Company headquartered in Miami, Florida, announced the appointment of Oscar Barreto, DPM, NP, FACFAS to Chief Medical Officer. In 1967, at the age of 5, Dr. Barreto arrived in Miami on a Freedom Flight with his mother and sister as they fled the Cuban communist regime. After 6 months in the US, his mother relocated them to Union City, New Jersey, where there was a growing Cuban community. They lived in a one-bedroom apartment and his mother worked two jobs to sustain them. Encouraging her children to work hard and finish their education as the only way out of poverty, a young Dr. Barreto began by working odd jobs painting apartments, shoveling snow, and cleaning basements. He graduated with Honors from the New York College of Podiatric Medicine in 1992 and was awarded the Pi Delta National Podiatry Honor Society Academic, Pi Delta National Podiatry Honor Society Service, and The Dr. Herbert Shain Memorial Scholarship Awards. He furthered his education by obtaining his MSN and Adult-Gerontology Primary Nurse Practitioner license. He is currently the Woundcare Program Director for Select Specialty Hospitals in Miami, Florida, and trains podiatric residents across the Country. He is a member of the American Academy of Nurse Practitioners (AANP), the American Podiatric Medical Association (APMA), and board certified by the American Board of Foot and Ankle Surgery.
Gilad Savion, Founder and CEO of Lavior Pharma is excited about Dr. Barreto’s addition to the team, “We are so glad to have Dr. Barreto join us as CMO. Dr. Barreto brings several decades of experience in dealing with complex wounds and I believe that his life experience and his vast understanding of wound management will help us to better position our superior supercharged hydrogel that can drastically reduce healing time and wound management cost. He will join our executive leadership team and lead our efforts to introduce Lavior woundcare treatments to clinicians across the country.”
Dr. Barreto shares, “I am looking forward to assisting Lavior in its primary goal to help patients heal. I have seen firsthand the superior outcomes that Lavior’s wound gel provides compared to other treatments, especially with refractory cases, allowing patients to heal much faster. Incorporating anti-inflammatory, anti-bacterial, and anti-fungal properties while promoting wound proliferation, and backed by over 12 years of extensive research, there is nothing else on the market that compares. Once clinicians see the results for themselves, they will also be convinced that Lavior’s all-organic, natural, and supercharged hydrogel should be considered as their first option for treating diabetic foot ulcers and other wounds.”
About Lavior Pharma Inc.
LAVIOR is the only company exclusively dedicated to the therapeutic diabetes skin care market. The LAVIOR skincare product line soothes and heals some of the most widespread and challenging skin problems – diabetic ulcers, wounds, burns, eczema/atopic dermatitis, bacterial and fungal infections, skin irritations, and cracked skin. LAVIOR’s line of products is based on the proven efficacy of the Inula AGS RIED botanical species. They are developed using the highest quality, pharmaceutical grade ingredients; manufactured and tested to deliver safe, effective, and compliant products. Backed by over 13 years of extensive research and clinical trials, proven clinical safety and efficacy, they consistently outperform conventional treatments.
For more information on Lavior Pharma and its products, please visit www.lavior.com
For Media or other Inquiries, please contact:
Anabelle Savion
Chief Marketing Officer
Phone: (+1) 9178373355
